

[View this email in your browser](#)



VALIDATING DIAGNOSTICS TO
COMBAT ANTIMICROBIAL RESISTANCE
BY OPTIMISING ANTIBIOTIC USE

 WWW.VALUE-DX.EU

FINAL NEWSLETTER

In September, the VALUE-Dx project came to an end after 5,5 years. We would like to sincerely thank the consortium for the great collaboration and effort that was poured into this project throughout the years!

In this final newsletter, you can read about our closing conference in Valencia, the innovative clinical algorithm, two insightful interviews & more!

Closing Conference recap

On 4 and 5 September, the VALUE-Dx consortium came together for the last time at the Closing Conference in Valencia! Over 80 experts shared key findings, including advancements in diagnosing community-acquired respiratory infections and insights from the ADEQUATE and PRUDENCE clinical studies. [Read our recap here.](#)



Concluding interview with Em. Prof. Herman Goossens

We sat down with Em. Prof. Herman Goossens, coordinator and project lead of VALUE-Dx. He explained how the project started, commented on the impact of the COVID-19 pandemic and discussed surprising



Clinical algorithm for diagnosing CA-ARTIs

Work package 1 of the VALUE-Dx project has developed an innovative clinical algorithm that improves accuracy and efficiency by integrating multiple diagnostic tests and clinical data. With a focus on flexibility and performance, this new approach is adaptable across diverse healthcare settings, optimising cost while maintaining high diagnostic standards. [Discover more here.](#)




AMR expert interview with Dr. Arjana Tambic



We interviewed Dr. Arjana Tambic Andrasevic, a leading Croatian expert on antimicrobial resistance! Dr. Tambic shared her insights on the challenges of AMR, the importance of robust surveillance, and the critical role of rapid diagnostics. Read this deep dive into the fight against AMR and the strategies needed to safeguard our future [here.](#)

New publication from the social sciences team

A new VALUE-Dx paper was recently published in the Journal of Antimicrobial Chemotherapy. It's a systematic review that explores healthcare professionals' and patients' views on using point-of-care tests (POCTs) for managing respiratory infections in primary care. The study highlights mixed opinions and identifies key factors that influence POCT use, recommending multi-level interventions to ensure effective implementation. This could guide policymakers in improving healthcare outcomes through better POCT integration. [Read the paper here.](#)



The recording of the VALUE-Dx symposium at this year's ERS Congress on 10 September is now available. The topic revolved around the value of in vitro diagnostic tests to reduce antimicrobial resistance & improve patient outcomes. [Watch it here.](#)

There is still lots of interesting news to come following these years of work.
Keep an eye on:

- the [VALUE-Dx E-Learning Platform](#) hosted by ERS
- our VALUE-Dx [X](#) (formerly known as Twitter) and [LinkedIn](#) accounts



Copyright © 2022 VALUE-Dx, All rights reserved.



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.